<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. Furthermore, increase of the concentrations of the progestin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an estroprogestin contraceptive with at leaset 30µg of ethinylestradiol. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase pf the plasma concentrations of elvitegravir by decrease of its metabolism by the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With the elvitegravir co-administered with the cobicistat [sic], clinical monitoring. Limit the maximum dose of itraconazole to 200 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of elvitegravir by decrease of its metabolism by the ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avec the elvitegravir co-administered with the cobicistat [sic], clinical monitoring. Limit the maximum dose of ketoconazole to 200 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the minimal concentrations of elvitegravir</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
